Intelligence Into The Pharmaceutical Industry Development Trend

With the rise of a new generation of information technology and the development of many high-tech fields, a series of cutting-edge technologies represented by artificial intelligence has begun to shine in various traditional fields, of which the integration of artificial intelligence and pharmaceutical industry development is particularly noteworthy. Especially in pharmaceuticals, is constantly providing strong help.

It is understood that new drug research and development has always been time-consuming, high cost, low success rate of research and development, long return cycle, risk and other problems, so in recent years, with the continuous development of science and technology, more and more companies and researchers began to use "artificial intelligence" to the pharmaceutical R & D and marketing links, and attempts to AI algorithms through artificial intelligence technology.

To further enhance the success rate of new drug development, reduce manufacturing costs and research and development time. Currently, companies including Bayer, Pfizer, Novartis, AstraZeneca, Takeda and others have begun to invest and collaborate with AI startups in order to increase clinical support and access to innovative drug structures.

For example, in April this year, PathAI and GlaxoSmithKline (GSK) jointly announced a multi-year strategic R&D collaboration to accelerate scientific research and drug development projects in oncology and non-alcoholic steatohepatitis (NASH) using PathAI's digital pathology technology platform (including its AIM-NASH tool).

In addition, Insight also announced an R&D collaboration with the translational team at the University of Zurich. The collaboration agreement shows that the MIKADO group will use its multi-omics database from preclinical models and cellular models of cystinosis to identify the cellular and molecular pathways that lead to life-threatening complications in patients with cystine storage disease through InSys' artificial intelligence target discovery platform, PandaOmics.

In addition to accelerating new drug development through intelligent platforms, a large number of pharmaceutical industry companies have also started to promote themselves for intelligent transformation in recent years.

For example, in 2021, Benxi Sankyo invested 40 million RMB in the intelligent transformation of its production area. This stage of transformation is mainly the preparation workshop to digital management of the production and manufacturing process.

From the current point of view, it is clear that intelligent transformation has become an important grasp of pharmaceutical companies to achieve cost reduction and efficiency, as well as to promote the high-quality development of the pharmaceutical industry.

It is worth noting that pharmaceutical equipment is an important means of pharmaceutical production, representing the level of production of the pharmaceutical industry, affecting the quality of drugs. Therefore, the industry believes that, in the context of the current pharmaceutical industry to promote intelligent transformation, the degree of intelligence of pharmaceutical equipment will also be more and more attention by pharmaceutical companies.

In fact, China's pharmaceutical equipment industry has opened the process of intelligent upgrading and transformation, such as East Fulong, Chutian Technology and Canaan Technology and other enterprises in the product intelligence research and development has been steadily, while the results are also emerging.

Such as Canaan Technology, with the development of intelligent manufacturing trend, it is accelerating the transformation from "manufacturing" to "intelligent manufacturing", the second half of 2021, its total investment of 1 billion yuan of intelligent pharmaceutical equipment manufacturing project, there are three standardized production workshop has been all topped. In the second half of 2021, its intelligent pharmaceutical equipment manufacturing project with a total investment of 1 billion yuan, three standardized production workshops have all been topped out, and the rest are in orderly progress, scheduled to be completed in 2023.

In addition, Yantai Huibao, through innovative research and development, has also made its products reach a series of programmed intelligence and automation such as automatic feeding, automatic locking, photoelectric tracking, automatic turning, and repair of faults.

It is understood that in 2021, it also made a series of programs from automatic feeding to automatic picking up at the request of customers, and a series of things such as automatic positioning of feeding process, automatic locking, photoelectric tracking, automatic turning, and automatic temperature control, repair of alarm system, and water level control are incorporated in the modularization, and the feeding action is always carried out through the modularized series connection, thus achieve the purpose of reducing industrial labor intensity and improving production efficiency.

At present, many pharmaceutical companies in the product intelligence level is constantly improving at the same time, the business is also moving toward the direction of multiple types, intelligent overall solution providers.

The industry is expected to continue to upgrade with the pharmaceutical industry intelligence, the future of the pharmaceutical equipment industry will also usher in a huge change, and with the automation, intelligent products, to further help the whole industry in the direction of high quality development.